European Allergen Manufacturers Group

Hay fever and asthma involve about 25% of the population in industrialised countries.

The optimal preventive treatment is based on induced tolerance by repeated administration of products from the sources of the allergy such as pollen, house dust mites and pets. This treatment - allergen specific Immunotherapy - involves allergen vaccines, also called allergen extracts.

The objective of EAMG is to ensure a favorable environment for optimal use of allergen extracts in the interest of the allergy specialist and the patients.

The 29th Congress of the European Academy of Allergy and Clinical Immunology will be held in London from June 5 to 9 2010. The members of EAMG supports the educational activities during this meeting with several symposia focusing on the potential of and benefits from allergen specific immunotherapy. New products and concepts including the latest technology in allergen administration and structure will be discussed.

lays down the quality recommendations for allergen products of used for specific immunotherapy (SIT) or in vivo diagnosis of immunoglobulin E (IgE) - mediated allergic diseases. These guidelines addresses issues of study design, efficacy and safety for allergen products being developed for specific immunotherapy of allergic diseases.

The WAO website is supported through an
unrestricted educational grant by EAMG

The World Allergy Organisation (WAO) that represents more than 70 national scientific allergy societies hostes the 22nd World Allergy Congress in Cancún, México, 4-8 December 2011.

. World Allergy Congress 2010

Allergen Specific Immunotherapy (SIT) is the only treatment that influences the basic course of the allergic diseases (WHO Position Paper 1998) and is so far the only treatment for respiratory allergic diseases which has shown the capacity to prevent development of asthma (WHO Allergic Rhinitis and its impact on Asthma report 2007 – update).